—
No price history
Clinical trials
catalyst calendar across sponsors →Studies where COGT is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
11 interventional · 1 observational · 2 expanded access · 1 with posted results
Held by 15 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, Balyasny Asset Management L.P., D. E. Shaw & Co., Inc., MILLENNIUM MANAGEMENT LLC, CITADEL ADVISORS LLC, +10 more) · FINRA short interest 10.5 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid TumorsNCT07383506Incidence and grade of Adverse Events (AEs) and Serious Adverse Events (SAEs) [Phase 1a]Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: CGT6297 | PIK3CA Mutations, Advanced Solid Tumors, Adult, Endometrial Cancer, HR Positive/HER-2 Negative Breast Cancer, HER2-low Breast Cancer | 90 | Jul 2029 | ≤ 1,077 d | 2026-07-01 |
| A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid TumorsNCT07361562Incidence and grade of Adverse Events (AEs) and Serious Adverse Events (SAEs) [Part A]Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: CGT4255 | Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer, ERBB2 Gene Amplification, HER2 Overexpression, Non-Small Cell Lung Cancer, HER2 | 100 | May 2028 | ≤ 651 d | 2026-02-27 |
| A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid TumorsNCT06777316Phase 1: Determine the maximum tolerated dose (MTD) and RP2D of CGT4859 - AEsNon-randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: CGT4859 | Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma, Other Solid Tumors, Adult, FGFR2 Gene Fusion/Rearrangement, FGFR2 Gene Amplification, FGFR2 Gene Short Variants, FGFR3 Gene Fusion/Rearrangement, FGFR3 Gene Amplification, FGFR3 Gene Short Variants, FGFR2 Genetic Alterations, FGFR3 Genetic Alterations, Advanced Solid Tumors | 110 | Mar 2027 | ≤ 224 d | 2026-04-17 |
| (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal TumorsNCT05208047Part 1a - pharmacokinetics - CmaxRandomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: CGT9486, CGT9486, Sunitinib, Sunitinib, Midazolam, CGT9486, Sunitinib, CGT9486, Sunitinib | Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer | 482 | 2025-09-30actual | — | 2026-06-16 |
| (Apex) Bezuclastinib in Patients With Advanced Systemic MastocytosisNCT04996875Part I: Identify clinically active and tolerable exposures of bezuclastinib in patients with AdvSMOpen-label · Treatment | Phase 2 | Recruiting | Drug: bezuclastinib | Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN), Mast Cell Leukemia (MCL), Aggressive Systemic Mastocytosis (ASM) | 140 | 2025-09-19actual | — | 2026-07-31 |
| (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic MastocytosisNCT05186753Part 1: Determine recommended dose of bezuclastinib (CGT9486) in subjects with NonAdvSMRandomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: Bezuclastinib Tablets (Formulation A), Bezuclastinib Tablets (Formulation B), Placebo Tablets | SSM, Mastocytosis, Indolent, Mastocytosis, Systemic, Mastocytosis, ISM, BMM, Smoldering Systemic Mastocytosis, Bone Marrow Mastocytosis | 237 | 2025-05-22actual | — | 2026-05-22 |
| Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell ProductNCT02840110observationalLong-term safety of ACTR T cell product as assessed by overall survival | — | Terminatedsponsor's stated reason: Business Decision | Other: ACTR T Cell Product | B Cell Lymphomas, Multiple Myeloma, Solid Tumor, HER-2 Protein Overexpression | 22 | 2020-10-23actual | — | 2021-10-11 |
| Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell LymphomaNCT03189836Safety as assessed by dose limiting toxicities (DLTs)Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Business decision | Biological: ACTR707, rituximab | Lymphoma | 26 | 2020-09-21actual | — | 2021-10-11 |
| CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid TumorsNCT02401815results2025-02-14Part 1: Recommended Phase 2 Dose (RP2D) of CGT9486Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: CGT9486, Pexidartinib, Sunitinib | Gastrointestinal Stromal Tumors | 51 | 2020-05-11actual | — | 2025-02-14 |
| Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor CancersNCT03680560Safety and tolerability of ACTR T cell product with trastuzumab as assessed by committee review of dose limiting toxicities (DLTs), incidence and severity of adverse events (AEs) and clinically significant abnormalities of laboratory valuesOpen-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Business Reasons | Biological: ACTR T Cell Product · Drug: Trastuzumab | Solid Tumor, HER-2 Protein Overexpression | 6 | 2020-03-12actual | — | 2020-03-31 |
| Study of ACTR087 in Subjects With Relapsed or Refractory B-cell LymphomaNCT02776813Safety as assessed by dose limiting toxicities (DLTs)Open-label · Treatment | Phase 1 | Completed | Biological: ACTR087, rituximab | Lymphoma | 34 | 2020-02-12actual | — | 2020-03-31 |
| Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple MyelomaNCT03266692Safety and tolerability of ACTR087 in combination with SEA-BCMAOpen-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Business reasons | Biological: ACTR087, SEA-BCMA | Multiple Myeloma, Multiple Myeloma in Relapse, Refractory Multiple Myeloma | 15 | 2019-10-01actual | — | 2020-03-30 |
| Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic MastocytosisNCT06915766expanded access | — | Available | Drug: Bezuclastinib | Systemic Mastocytoses, Indolent, Systemic Mastocytoses, Aggressive | — | — | — | 2026-07-13 |
| Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal TumorsNCT06948955expanded access | — | Available | Drug: Bezuclastinib, Sunitinib | Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors | — | — | — | 2026-07-13 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19